Inhaled XXXX therapy and risk of @entity8 : a systematic review and meta-analysis of randomized trials.

@entity1 @entity8 @entity649 @entity120 @entity23 @entity842 @entity1576 @entity810
INTRODUCTION: Inhaled @entity842 (iNO) is an important therapy for @entity649 ( @entity649 ), @entity120 and pediatric @entity1576 . Safety concerns regarding iNO and @entity8 have been reported; however, there are currently no systematic reviews on this issue. Our objective was to evaluate published @entity23 ( @entity23 ) to ascertain the risk of @entity8 associated with iNO therapy in @entity1 with and without @entity649 . METHODS: A systematic review of databases was performed to identify @entity23 which compared iNO with controls up to September 2014. Effect estimates for risk ratio (RR) of @entity810 ( @entity810 ) were pooled using a random-effects model. RESULTS: Ten @entity23 involving 1363 @entity1 were included. Inhaled @entity842 significantly increased the risk of @entity810 compared with controls (RR, 1.4, 95%CI, 1.06 to 1.83, p   =   0.02). In the stratified analysis, a high cumulative-dose of iNO significantly increased the risk of @entity810 (RR, 1.52, 95%CI, 1.14 to 2.02, p   =   0.004), whereas medium and low cumulative-doses did not (RR, 0.64, 95%CI, 0.23 to 1.81 and RR, 0.56, 95%CI, 0.11 to 2.86 respectively). In subgroup analysis by study population, an increased risk of @entity810 was observed in @entity1 with @entity649 (RR, 1.55, 95%CI, 1.15 to 2.09, p   =   0.005) but not in those without (RR, 0.90, 95%CI, 0.49 to 1.67, p   =   0.75). CONCLUSIONS: The available data show that iNO therapy may increase the risk of @entity8 , especially with prolonged use and in @entity1 with @entity649 . The risk in pediatric population is unknown owing to limited data. We suggest monitoring renal function during iNO therapy, and that future trials of iNO should evaluate renal safety.
